HPV Vaccine Protect Girls from Cervical Cancer

HPV Vaccine Protect Girls from Cervical Cancer


Find Health Services


Need help?

Call our Infoline

on 1850 24 1850


Human Papilomavirus School Immunisation Programme


HPV vaccine - Protect now, for the Future HPV Doodle pink

September 2014

The HPV vaccine will protect girls from developing cervical cancer when they are adults. It is available free of charge from the HSE for all girls in 1st year of second level school.

The Health Service Executive (HSE) will continue to target all girls in 1st year of second level schools in a school based programme to ensure high vaccine uptake.

Vaccine are in mainly given to girls in second-level schools by HSE Immunisation teams, with some girls being invited to special clinics for their vaccines.

From September 2014

  • all girls less than 15 years of age will require two doses of HPV vaccine given at 0 and 6 months
  • all girls ages 15 years and older will require three doses of the HPV vaccine given at 0 and 6 months and the third dose will be given at least three months after the second dose.

The programme aims to achieve a high uptake of over 80% for a completed vaccine course.

When HPV vaccines are given in school the HSE will let you know the date of immunisations. If a student misses that immunisation in school, the HSE will arrange for the student to be vaccinated at a HSE clinic.

To read more about HPV please visit the following pages

  • HPV and cervical cancer
  • HPV vaccination programme
  • HPV vaccine

HPV vaccine - Protect now, for the Future

The following information materials are available for parents of girls in First Year of second level schools or equivalent in special schools.

Information Booklet - English | Irish | Arabic | Simplified Chinese | German | French | Polish | Portuguese | Romanian | Russian

Consent Form - English and Irish combined form

Post Vaccination Advice - English | Irish

If you have any questions please contact the schools immunisation programme office in your area. The contact phone numbers are available in English and Irish.


More Information about HPV can be found at the following websites:

HPV vaccine - Protect now, for the Future

The following information materials are available for healthcare professionals who carry out the programme.

  • Gardasil - Summary of Product Characteristics (SPC)
  • Gardasil - Patient Information Leaflet (PIL)
  • Royal College of Physicians of Ireland - Immunisation Guidelines for Ireland. Chapter 10 - Human Papillomavirus
  • School Immunisation Programme Guidelines for Staff 2014/2015 - Version 4.1 (updated September 2014)
  • HPV Frequently Asked Questions - Version 11.0 (Updated August 2014)

(Please note when you click on the SPC or PIL for Gardasil you will be leaving our website www.immunisation.ie)

Medication Protocol for the School Immunisation Programme

  • Gardasil Medication Protocol (September 2014)
  • Anaphylaxis Protocol (September 2014)

HPV vaccine - Protect now, for the Future

Gardasil safety reports

  • Post-licensure data for Gardasil distributed in the United States from 2006 to end of 2008 was published in JAMA2009. Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta HS, Ball R, Miller N, Braun MM, Markowitz LE, Iskander J. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009 Aug 19;302(7):750-7 (available at http://jama.ama-assn.org/cgi/content/full/302/7/750)
  • The Irish Medicines Board published a report on the first year of the HPV vaccination programme in Ireland. Overview of national monitoring experience with Gardasil. 19 July 2011. (available at http://www.hpra.ie/docs/default-source/Safety-Notices/imb_gardasil_webupdate_19jul2011.pdf)
  • World Health Organization, Global Advisory Committee on Vaccine Safety. Update on human papillomavirus vaccines. Weekly Epidemiological Record 2013 29 309-312. (available at http://www.who.int/wer/2013/wer8829.pdf)
  • Centers for Disease Control and Prevention. Human Papillomavirus Vaccination Coverage Among Adolescent Girls, 2007-2013, and Postlicensure Vaccine Safety Monitoring, 2006-2014 -- United States. MMWR 2014; 63 (29) 620-624 available at http://www.cdc.gov/mmwr/pdf/wk/mm6329.pdf
  • Arnheim-Dahlström L, Pasternak B, Svanström H, Sparén P and Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 2013;347:f5906 (available at http://www.bmj.com/content/347/bmj.f5906)

Please use the following links to access presentation slides from meetings held in May and August 2010 relating to HPV

  • Training slides from the HPV training programme held on the 6th May 2010.
  • Copy of Prof Margaret Stanleys presentation titled HPV VLP Vaccine Development and Impact. Prof Stanley spoke to an audience on the 31st August 2010.


HPV Doodle single